Correlation of serum and saliva theophylline concentration after administration of a sustained release preparation
- PMID: 7308276
- DOI: 10.1007/BF00554670
Correlation of serum and saliva theophylline concentration after administration of a sustained release preparation
Abstract
The correlation between serum and saliva levels of theophylline was investigated in seven healthy volunteers after multiple dose administration of a low dose (300 mg/day) and a high dose (900 mg/day) of a sustained release theophylline preparation (Theo-Dur). Tablets were taken for five days, at 8 a. m. and 8 p. m. and a last dose was taken on Day 6 at 8 a. m. Fourteen serum and saliva samples were collected simultaneously during the dosing period and for up to 32 h after the last dose. On the 300 mg/day regimen the level in saliva was 55.3% of the serum level, with an overall variability of 6.7% and an intrasubject variability of 10.5%. After 900 mg/day, the saliva concentration was 55.5% of the serum concentration, with an overall variability of 7.6% and an intrasubject variability of 12.7%. A good correlation was found between both determinations (r = 0.99), which suggests that saliva levels could be used to monitor theophylline after administration of a sustained release tablet.
Similar articles
-
Pharmacokinetics of sustained release theophylline in low and high multidose regimens.Br J Clin Pharmacol. 1981 Nov;12(5):647-51. doi: 10.1111/j.1365-2125.1981.tb01283.x. Br J Clin Pharmacol. 1981. PMID: 7332728 Free PMC article.
-
Study of bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms as assessed by salivary data: Part II.Int J Clin Pharmacol Ther Toxicol. 1986 Apr;24(4):196-201. Int J Clin Pharmacol Ther Toxicol. 1986. PMID: 3710632
-
Variations in absorption of theophylline from two sustained-release products.Clin Ther. 1986;8(6):646-54. Clin Ther. 1986. PMID: 3791362 Clinical Trial.
-
Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.J Asthma. 1986;23(3):113-22. doi: 10.3109/02770908609077485. J Asthma. 1986. PMID: 3528119 Clinical Trial.
-
A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.Clin Pharmacokinet. 1984 Mar-Apr;9(2):95-135. doi: 10.2165/00003088-198409020-00001. Clin Pharmacokinet. 1984. PMID: 6370542 Review.
Cited by
-
Theophylline.Clin Rev Allergy. 1983 Mar;1(1):73-85. doi: 10.1007/BF02991318. Clin Rev Allergy. 1983. PMID: 6367926 Review. No abstract available.
-
Reproducibility of saliva and plasma theophylline levels following single dose administration of two sustained release preparations.Br J Clin Pharmacol. 1983 Apr;15(4):407-10. doi: 10.1111/j.1365-2125.1983.tb01522.x. Br J Clin Pharmacol. 1983. PMID: 6849775 Free PMC article.
-
Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients.Antimicrob Agents Chemother. 1991 Jun;35(6):1137-41. doi: 10.1128/AAC.35.6.1137. Antimicrob Agents Chemother. 1991. PMID: 1929255 Free PMC article. Clinical Trial.
-
Pharmacokinetics of sustained release theophylline in low and high multidose regimens.Br J Clin Pharmacol. 1981 Nov;12(5):647-51. doi: 10.1111/j.1365-2125.1981.tb01283.x. Br J Clin Pharmacol. 1981. PMID: 7332728 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources